Alinidine

Alinidine
Clinical data
ATC code	none;
Legal status
Legal status	In general: uncontrolled;
Identifiers
	IUPAC name N-(2,6-dichlorophenyl)-N-(prop-2-en-1-yl)-4,5-dihydro-1H-imidazol-2-amine;
CAS Number	33178-86-8 ;
PubChem CID	36354;
ChemSpider	33429 ;
UNII	E7IDJ8DS1D;
ChEMBL	ChEMBL278581 ;
CompTox Dashboard (EPA)	DTXSID4022571 ;
ECHA InfoCard	100.164.275
Chemical and physical data
Formula	C12H13Cl2N3
Molar mass	270.16 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc2cccc(Cl)c2N(/C1=N/CCN1)C\C=C;
	InChI InChI=1S/C12H13Cl2N3/c1-2-8-17(12-15-6-7-16-12)11-9(13)4-3-5-10(11)14/h2-5H,1,6-8H2,(H,15,16) ; Key:OXTYVEUAQHPPMV-UHFFFAOYSA-N ;
	(what is this?) (verify)

Alinidine (ST567) is a negative chronotrope that was developed in the 1970s and 1980s. It causes bradycardia by inhibiting the pacemaker current by altering the maximal channel conductance and alter the voltage threshold.^[1] The development of alinidine was halted because it was not sufficiently specific for its target. It also has a blocking effect on calcium channels and potassium channels. It also causes elongation of re-polarisation after an action potential.^[2]

Alinidine did not improve outcomes among patients with acute myocardial infarction in a randomized controlled trial.^[3]

References

^ Snyders DJ, Van Bogaert P-P: Alinidine modifies the pacemaker current in sheep Purkinje fibers. Pflügers Arch 1987, 410:83-91
^ Current Opinion in Pharmacology 2007, 7:208–213
^ Van de Werf F, Janssens L, Brzostek T, Mortelmans L, Wackers FJ, Willems GM, et al. (1993). "Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy". J Am Coll Cardiol. 22 (2): 407–16. doi:10.1016/0735-1097(93)90044-2. PMID 8335810.

[1] Snyders DJ, Van Bogaert P-P: Alinidine modifies the pacemaker current in sheep Purkinje fibers. Pflügers Arch 1987, 410:83-91

[2] Current Opinion in Pharmacology 2007, 7:208–213

[pmid8335810-3] Van de Werf F, Janssens L, Brzostek T, Mortelmans L, Wackers FJ, Willems GM, et al. (1993). "Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy". J Am Coll Cardiol. 22 (2): 407–16. doi:10.1016/0735-1097(93)90044-2. PMID 8335810.

[1]

[2]

[3]